title: Expression of perlecan proteoglycan in the infarct zone of mouse myocardial infarction.
abstract: Perlecan, a basal lamina proteoglycan, has been shown to interact with other extracellular matrix (ECM) components, especially type IV collagen, and is thus involved in ECM formation. Perlecan has also been postulated to promote growth factor-receptor interactions, including the binding of basic fibroblast growth factor (bFGF) to its receptor, and to enhance mitogenesis and angiogenesis. To test our hypothesis that perlecan is increased in the myocardial infarct zone, we examined perlecan expression after experimentally induced myocardial infarction in BALb/c mice by the methods of in situ hybridization, Northern blotting, and immunohistochemistry. In situ hybridization revealed mRNA signals for perlecan in the infarct marginal zone on day 2 and in the infarct interior zone around infarct granulation tissue on day 7. On day 14 the signals were observed at the center point of the infarct. The signals were detected in spindle-shaped mesenchymal cells (fibroblasts and myofibroblasts). Some surviving myocytes in the infarct marginal zone also showed positive signals. The sequential changes in the perlecan mRNA signal distribution paralleled those for type IV collagen mRNA. Northern blotting demonstrated increased expression of perlecan consistent with the observations of in situ hybridization. Immunopositive staining for perlecan was observed in the infarct zone around granulation tissue on day 7 and in the entire infarct zone on days 14-28. Immunostaining for bFGF was localized surrounding the infarct granulation tissue on day 7 and overlapped with perlecan immunostaining. The present results demonstrated the expression of perlecan by spindle-shaped mesenchymal cells (fibroblasts and myofibroblasts) and some surviving myocytes in the myocardial infarct, indicating the contribution of perlecan to the pathological course of myocardial infarction.
authors.affiliation: Department of Internal Medicine I, Okayama University Medical School, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Nakahama
authors.forename: T
authors.initials: T
authors.lastname: Murakami
authors.forename: S
authors.initials: S
authors.lastname: Kusachi
authors.forename: I
authors.initials: I
authors.lastname: Naito
authors.forename: K
authors.initials: K
authors.lastname: Takeda
authors.forename: H
authors.initials: H
authors.lastname: Ohnishi
authors.forename: I
authors.initials: I
authors.lastname: Komatsubara
authors.forename: T
authors.initials: T
authors.lastname: Oka
authors.forename: Y
authors.initials: Y
authors.lastname: Ninomiya
authors.forename: T
authors.initials: T
authors.lastname: Tsuji
mesh_terms: D000818:Animals; D015152:Blotting, Northern / Q000379:methods; D015870:Gene Expression; D019812:Heparan Sulfate Proteoglycans / Q000096:biosynthesis* / Q000235:genetics; D007150:Immunohistochemistry / Q000379:methods; D017403:In Situ Hybridization / Q000379:methods; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009203:Myocardial Infarction / Q000378:metabolism* / Q000473:pathology; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology
chemical_list: D019812:Heparan Sulfate Proteoglycans; C071927:perlecan